FGFR

Inhibitory Selectivity
Catalog No.Inhibitor Name FGFRFGFR1FGFR2FGFR3FGFR4Other
A10080Ponatinib
****
Abl,PDGFRα,VEGFR2
A11159BGJ398
****
****
****
**
VEGFR2,Lyn,Kit
A10137Nintedanib
**
**
**
*
VEGFR3,VEGFR2,LCK
A10703PD173074
**
VEGFR2,c-Src
A11411Dovitinib
***
***
FLT3,c-Kit,VEGFR3/FLT4
A11075AZD4547
****
****
****
*
KDR,IGFR
A10715Danusertib
**
Aurora A,Abl,TrkA
A10953Orantinib
*
PDGFRβ,Flk1
A10254Brivanib
*
VEGFR2,Flk1,VEGFR1
A10198Dovitinib Dilactic Acid
***
***
FLT3,c-Kit,VEGFR3/FLT4
A11753MK-2461
**
**
**
A10162Brivanib Alaninate
*
VEGFR2,Flk1,VEGFR1
A13211SSR128129E
*
VEGFR2,PDGFRβ
A11558SU5402
**
A15534BLU9931
*
*
*
****
A12357FIIN-2
****
***
**
**
FLT3,c-Kit,VEGFR3/FLT4
A14415CH5183284
***
***
***
*
VEGFR2
A11244LY2874455
****
****
***
***
A15957Erdafitinib
A10508KW-2449
**
FLT3, Bcr-Abl, Aurora A, PDGFRβ, IGF-1R, EGFR
A10699Pazopanib HCl
*
VEGFR1, VEGFR2, VEGFR3, PDGFR, c-Kit, c-Fms
A11518Pazopanib
*
VEGFR1, VEGFR2, VEGFR3, PDGFR, c-Kit, c-Fms
A13111R 1530
*
Chk2, KDR, FGFR, Aurora A, Cdk2, VEGFR-2, PDGFRβ
A15073E-3810
***
**
VEGFR1, VEGFR2, VEGFR3
A15848FIIN-3
***
**
**
**
A15957Alofanib (RPT835)

Notes:
1.Hover mouse over " * " to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of " * " is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.



Items 1 to 25 of 27 total

per page
Page:
  1. 1
  2. 2

Set Descending Direction
Catalog No. Product Name Application Product Information
A15946

Alofanib (RPT835)

FGFR2 Inhibitor
Alofanib is a potent and selective allosteric inhibitor of FGFR2 with potential anticancer activity.
A10080 SALE

AP24534 (Ponatinib)

BCR-ABL inhibitor
AP24534 (Ponatinib) is a potent multi-kinase and pan-BCR-ABL inhibitor.
A11075 SALE

AZD4547

FGFR inhibitor
AZD4547 is a potent, selective and orally active pan-FGFR inhibitor, with IC50s of 0.2, 2.5, 1.8 and 165 nM for FGFR1, 2, 3 and 4, respectively.
A11159 SALE

BGJ398 (NVP-BGJ398)

FGFR Inhibitor
BGJ398 is a potent and selective inhibitor with potential antiangiogenic and antineoplastic activities of fibroblast growth factor receptor (FGFR) tyrosine kinases 1, 2, 3 and 4 (with IC50 values of 0.9, 1.4, 1.0 and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4 respectively).
A10137 SALE

Bibf1120 (Vargatef)

VEGFR inhibitor
BIBF1120 (Vargatef) is a novel triple angiokinase inhibitor that inhibits three growth factor receptors simultaneously: VEGFR, PDGF and FGFR.
A15534 SALE

BLU9931

FGFR inhibitor
BLU9931 is the first selective small molecule inhibitor of FGFR4 with IC50 of 3 nM; less potent for FGFR1/2/3(IC50> 150 nM),
A10254 SALE

Brivanib (BMS-540215)

VEGFR-2 inhibitor
Brivanib (BMS-540215) is a VEGFR -2 inhibitor with an IC50 of 25 nM and Ki of 26 nM.
A10162

Brivanib alaninate (BMS-582664)

VEGFR inhibitor
Brivanib alaninate (BMS-582664) is a dual tyrosine kinase inhibitor of VEGFR and FGFR signaling.
A10715 SALE

Danusertib (PHA-739358)

Aurora inhibitor
Danusertib (PHA-739358) is a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor
A14415

Debio-1347 (CH5183284)

FGFR1/2/3 inhibitor
Debio-1347 is an orally bioavailable inhibitor of the fibroblast growth factor receptor subtypes 1 (FGFR-1), 2 (FGFR-2) and 3 (FGFR-3), with potential antineoplastic activity.
A11411 SALE

Dovitinib (TKI-258)

RTK inhibitor
Dovitinib is a small-molecule multitargeted receptor tyrosine kinase inhibitor, which inhibits Ba/F3 cells transformed to IL3 independence by ZNF198-FGFR1 or BCR-FGFR1 with IC50 values of 150 nM and 90 nM, respectively.
A10198 SALE

Dovitinib Dilactic acid (TKI258 Dilactic acid)

RTK inhibitor
Dovitinib is a small-molecule multitargeted receptor tyrosine kinase inhibitor, which inhibits Ba/F3 cells transformed to IL3 independence by ZNF198-FGFR1 or BCR-FGFR1 with IC50 values of 150 nM and 90 nM, respectively.
A15073

E-3810

VEGFR/FGFR Inhibitor
E-3810 is a potent and selective dual inhibitor of VEGF and FGF receptors with IC50 values of 7 nM, 25 nM, 10 nM, 17.5 nM and 82.5 nM for VEGFR-1, VEGFR-2, VEGFR-3, FGFR-1 and FGFR-2, respectively.
A15957

Erdafitinib

FGFR inhibitor
Erdafitinib is a potent and selective orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic activity.
A12357 SALE

FIIN-2

FGFR Inhibitor
FIIN-2 is an irreversible inhibitor of FGFR1-4 with IC50 values of 3.1, 4.3, 27, and 45 nM, respectively.
A15848

FIIN-3

Irreversible FGFR inhibitor
FIIN-3 is a potent, selective, irreversible and the next-generation covalent FGFR inhibitor.
A10508 SALE

KW-2449

Aurora Inhibitor
KW-2449 is a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase.
A11244 SALE

LY 2874455

-
LY2874455 is a novel and potent FGF/FGFR Inhibitor.
A11753

MK-2461

c-Met Inhibitor
MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
A15194

NVP-BGJ398 phosphate

FGFR Inhibitor
NVP-BGJ398 phosphate is a novel selective, pan-specific FGFR inhibitor with IC50 of 0.9, 1.4, and 1 nM for FGFR1, FGFR2, and FGFR3, respectively; >40-fold selective for FGFR versus FGFR4 and VEGFR2, and little activity to Abl, Fyn, Kit, Lck, Lyn and Yes.
A11518 SALE

Pazopanib (GW-786034)

VEGFR inhibitor
Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit that blocks tumor growth and inhibits angiogenesis.
A10699 SALE

Pazopanib HCl (GW786034)

VEGFR/PDGFR/FGFR inhibitor
Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit that blocks tumor growth and inhibits angiogenesis.
A10703 SALE

PD173074

FGFR Inhibitor
PD173074 is a potent, cell permeable and ATP competitive inhibitor of FGFR and VEGFR.
A13111 SALE

R1530

Chk2, KDR, FGFR, Aurora A & Cdk2 inhibitor
R1530 is a pyrazolobenzodiazepine small molecule with potential antiangiogenesis and antineoplastic activities. R1530 is also a mitosis-angiogenesis inhibitor (MAI) that inhibits multiple receptor tyrosine kinases involved in angiogenesis, such as vascular endothelial growth factor receptor (VEGFR)-1, -2, -3, platelet-derived growth factor receptor (PDGFR) beta? FMS-like tyrosine kinase (Flt)-3, and fibroblast growth factor receptor (FGFR) -1, -2.
A13211

SSR128129E

FGFR1 inhibitor
SSR128129E is an orally-active and allosteric FGFR1 inhibitor with IC50 of 1.9 uM

Items 1 to 25 of 27 total

per page
Page:
  1. 1
  2. 2

Set Descending Direction